

D-2914

8/Suppl
prior art used

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT

In re application of) Group Art Unit: 1615
 WOODWARD et al.)
 Serial No. 09/847,935) Examiner: Fubara, B.
 Filed: May 3, 2001)
 For: COMPOSITIONS HAVING)
 ENHANCED PHARMACOKINETIC)
 CHARACTERISTICS)

I hereby certify that this correspondence is being
 transmitted via facsimile to the Commissioner for
 Patents in Washington, DC 20231, to fax number 703-305-3592,
 on or before September 16, 2002

Andrea UxaDate: 9/16/02

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
 Washington, D.C. 20231

Dear Sir:

Applicant wishes to call to the attention of the Examiner the documents cited on the accompanying Form PTO-1449. No concession is made that these documents are prior art, and applicant expressly reserves the right to antedate the documents as may be appropriate. Applicant requests that each of these documents be made of record in the above-identified application.

This SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT is being filed pursuant to 37 CFR 1.97(c) and is accompanied by a certification as specified in 37 CFR 1.97(e).

CERTIFICATION UNDER 37 CFR 1.97(e)

Each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication (the


BEST AVAILABLE COPY

D-2914

2

International Search Report) from a foreign patent office (The European Patent Office) acting as the International Search Authority in a counterpart foreign (PCT) patent application no more than three months prior to the filing of this Supplemental Information Disclosure Statement (a copy of the International Search Report is enclosed).

Respectfully submitted,


Frank J. Uxa
Attorney for Applicant
Reg. No. 25,612
4 Venture, Suite 300
Irvine, CA 92618
(949) 450-1750
Facsimile (949) 450-1764

FJUxa/ac

BEST AVAILABLE COPY